Miller RJ, Kelly PH, Neumeyer JL (January 1976). "Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain". European Journal of Pharmacology. 35 (1): 77–83. doi:10.1016/0014-2999(76)90302-2. PMID943290.
Creese I, Padgett L, Fazzini E, Lopez F (July 1979). "3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors". European Journal of Pharmacology. 56 (4): 411–2. doi:10.1016/0014-2999(79)90274-7. PMID477735.
Menon MK, Clark WG, Neumeyer JL (November 1978). "Comparison of the dopaminergic effects of apomorphine and (−)-N-n-propylnorapomorphine". European Journal of Pharmacology. 52 (1): 1–9. doi:10.1016/0014-2999(78)90015-8. PMID569056.
Riffee WH, Wilcox RE, Smith RV (March 1979). "Stereotypic and hypothermic effects of apomorphine and N-n-propylnorapomorphine in mice". European Journal of Pharmacology. 54 (3): 273–7. doi:10.1016/0014-2999(79)90086-4. PMID570924.
Neumeyer JL, Reinhard JF, Dafeldecker WP, et al. (January 1976). "Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine". Journal of Medicinal Chemistry. 19 (1): 25–9. doi:10.1021/jm00223a006. PMID942751.
Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (October 1982). "Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines". Neuropharmacology. 21 (10): 953–61. doi:10.1016/0028-3908(82)90106-X. PMID6890636. S2CID23393175.
Argiolas A, Mereu G, Serra G, Melis MR, Fadda F, Gessa GL (January 1982). "N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors". Brain Research. 231 (1): 109–16. doi:10.1016/0006-8993(82)90011-7. PMID6799148. S2CID7139938.
nih.gov
pubmed.ncbi.nlm.nih.gov
Miller RJ, Kelly PH, Neumeyer JL (January 1976). "Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain". European Journal of Pharmacology. 35 (1): 77–83. doi:10.1016/0014-2999(76)90302-2. PMID943290.
Creese I, Padgett L, Fazzini E, Lopez F (July 1979). "3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors". European Journal of Pharmacology. 56 (4): 411–2. doi:10.1016/0014-2999(79)90274-7. PMID477735.
Menon MK, Clark WG, Neumeyer JL (November 1978). "Comparison of the dopaminergic effects of apomorphine and (−)-N-n-propylnorapomorphine". European Journal of Pharmacology. 52 (1): 1–9. doi:10.1016/0014-2999(78)90015-8. PMID569056.
Riffee WH, Wilcox RE, Smith RV (March 1979). "Stereotypic and hypothermic effects of apomorphine and N-n-propylnorapomorphine in mice". European Journal of Pharmacology. 54 (3): 273–7. doi:10.1016/0014-2999(79)90086-4. PMID570924.
Neumeyer JL, Reinhard JF, Dafeldecker WP, et al. (January 1976). "Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine". Journal of Medicinal Chemistry. 19 (1): 25–9. doi:10.1021/jm00223a006. PMID942751.
Benassi-Benelli A, Ferrari F, Quarantotti BP (December 1979). "Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats". Archives Internationales de Pharmacodynamie et de Thérapie. 242 (2): 241–7. PMID44457.
Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (October 1982). "Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines". Neuropharmacology. 21 (10): 953–61. doi:10.1016/0028-3908(82)90106-X. PMID6890636. S2CID23393175.
Argiolas A, Mereu G, Serra G, Melis MR, Fadda F, Gessa GL (January 1982). "N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors". Brain Research. 231 (1): 109–16. doi:10.1016/0006-8993(82)90011-7. PMID6799148. S2CID7139938.
semanticscholar.org
api.semanticscholar.org
Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (October 1982). "Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines". Neuropharmacology. 21 (10): 953–61. doi:10.1016/0028-3908(82)90106-X. PMID6890636. S2CID23393175.
Argiolas A, Mereu G, Serra G, Melis MR, Fadda F, Gessa GL (January 1982). "N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors". Brain Research. 231 (1): 109–16. doi:10.1016/0006-8993(82)90011-7. PMID6799148. S2CID7139938.